Table 2.
Baseline tertiles of ceramides and sphingomyelins and risk of AD by sex
| Men | Women | ||||
|---|---|---|---|---|---|
| Lipid | univariate HR (95% CI) | multivariate HR (95% CI) | univariate HR (95% CI) | multivariate HR (95% CI) | |
| Ceramide | |||||
| C16:0 | 2 vs. 1 | 2.03 (1.08, 3.84) | 1.68 (0.88, 3.19) | 1.23 (0.67, 2.25) | 1.29 (0.66, 2.51) |
| 3 vs. 1 | 2.30 (1.25, 4.21) | 2.26 (1.20, 4.23) | 1.27 (0.70, 2.31) | 0.74 (0.37, 1.50) | |
| C18:0 | 2 vs. 1 | 1.44 (0.85, 2.46) | 1.27 (0.74, 2.18) | 1.41 (0.78, 2.55) | 1.04 (0.53, 2.04) |
| 3 vs. 1 | 1.93 (1.15, 3.24) | 1.83 (1.07, 3.11) | 1.59 (0.92, 2.77) | 0.90 (0.48, 1.68) | |
| C20:0 | 2 vs. 1 | 1.22 (0.78, 1.92) | 1.29 (0.81, 2.04) | 1.08 (0.62, 1.89) | 1.06 (0.56, 2.00) |
| 3 vs. 1 | 1.32 (0.83, 2.09) | 1.50 (0.93, 2.42) | 1.17 (0.66, 2.06) | 0.67 (0.35, 1.27) | |
| C22:0 | 2 vs. 1 | 1.25 (0.78, 2.01) | 1.11 (0.68, 1.81) | 0.95 (0.52, 1.73) | 1.02 (0.50, 2.08) |
| 3 vs. 1 | 1.42 (0.91, 2.23) | 1.66 (1.04, 2.66) | 1.36 (0.78, 2.37) | 1.16 (0.59, 2.27) | |
| C24:0 | 2 vs. 1 | 1.33 (0.82, 2.16) | 1.20 (0.73, 1.96) | 1.01 (0.57, 1.80) | 1.28 (0.66, 2.47) |
| 3 vs. 1 | 1.49 (0.94, 2.35) | 1.67 (1.04, 2.69) | 1.14 (0.65, 2.02) | 1.13 (0.57, 2.25) | |
| C26:0 | 2 vs. 1 | 1.21 (0.76, 1.93) | 1.14 (0.70, 1.84) | 1.02 (0.55, 1.88) | 0.88 (0.44, 1.75) |
| 3 vs. 1 | 1.35 (0.86, 2.13) | 1.27 (0.80, 2.02) | 1.20 (0.67, 2.14) | 0.95 (0.48, 1.89) | |
| C22:1 | 2 vs. 1 | 0.88 (0.56, 1.39) | 0.72 (0.44, 1.15) | 1.20 (0.65, 2.21) | 0.87 (0.43, 1.74) |
| 3 vs. 1 | 1.04 (0.68, 1.59) | 1.02 (0.66, 1.57) | 1.21 (0.67, 2.17) | 0.81 (0.42, 1.55) | |
| C24:1 | 2 vs. 1 | 1.31 (0.84, 2.06) | 1.31 (0.82, 2.09) | 1.30 (0.74, 2.27) | 1.13 (0.61, 2.12) |
| 3 vs. 1 | 1.56 (1.01, 2.42) | 1.51 (0.97, 2.36) | 1.01 (0.55, 1.87) | 0.70 (0.36, 1.34) | |
| Sphingomyelins | |||||
| C16:0 | 2 vs. 1 | 1.01 (0.64, 1.59) | 0.92 (0.57, 1.47) | 0.90 (0.51, 1.60) | 0.65 (0.34, 1.21) |
| 3 vs. 1 | 1.24 (0.79, 1.93) | 0.96 (0.59, 1.57) | 0.96 (0.55, 1.69) | 0.50 (0.26, 0.97) | |
| C18:0 | 2 vs. 1 | 1.95 (1.25, 3.05) | 1.84 (1.15, 2.93) | 1.44 (0.77, 2.69) | 1.27 (0.63, 2.56) |
| 3 vs. 1 | 1.54 (0.97, 2.44) | 1.60 (0.97, 2.63) | 1.39 (0.75, 2.58) | 0.89 (0.44, 1.83) | |
| C20:0 | 2 vs. 1 | 0.81 (0.51, 1.28) | 0.74 (0.46, 1.20) | 0.94 (0.53, 1.65) | 1.01 (0.54, 1.89) |
| 3 vs. 1 | 1.46 (0.96, 2.23) | 1.20 (0.76, 1.90) | 0.91 (0.51, 1.63) | 0.74 (0.39, 1.41) | |
| C22:0 | 2 vs. 1 | 0.99 (0.62, 1.57) | 0.87 (0.54, 1.39) | 1.13 (0.65, 1.95) | 1.21 (0.66, 2.23) |
| 3 vs. 1 | 1.38 (0.89, 2.12) | 1.03 (0.64, 1.65) | 0.93 (0.50, 1.70) | 0.64 (0.33, 1.23) | |
| C24:0 | 2 vs. 1 | 1.06 (0.66, 1.71) | 0.69 (0.42, 1.13) | 1.21 (0.69, 2.14) | 1.15 (0.61, 2.19) |
| 3 vs. 1 | 1.61 (1.05, 2.46) | 1.37 (0.87, 2.15) | 1.03 (0.57, 1.85) | 0.86 (0.44, 1.67) | |
| C16:1 | 2 vs. 1 | 1.10 (0.72, 1.69) | 0.85 (0.55, 1.31) | 1.33 (0.74, 2.40) | 1.11 (0.59, 2.10) |
| 3 vs. 1 | 1.28 (0.81, 2.01) | 0.91 (0.57, 1.48) | 0.97 (0.54, 1.75) | 0.73 (0.39, 1.39) | |
| C18:1 | 2 vs. 1 | 1.55 (0.99, 2.43) | 1.51 (0.95, 2.40) | 1.52 (0.84, 2.78) | 1.12 (0.58, 2.17) |
| 3 vs. 1 | 2.00 (1.25, 3.18) | 1.86 (1.14, 3.03) | 0.98 (0.53 1.81) | 0.66 (0.32, 1.38) | |
| C20:1 | 2 vs. 1 | 1.17 (0.76, 1.81) | 1.03 (0.66, 1.62) | 1.93 (1.05, 3.53) | 1.53 (0.77, 3.02) |
| 3 vs. 1 | 1.88 (1.21, 2.93) | 1.58 (1.00, 2.52) | 1.08 (0.56, 2.07) | 0.71 (0.35, 1.45) | |
| C22:1 | 2 vs. 1 | 1.34 (0.86, 2.10) | 1.17 (0.73, 1.86) | 1.13 (0.63, 2.04) | 1.04 (0.54, 1.98) |
| 3 vs. 1 | 1.88 (1.19, 2.97) | 1.69 (1.04, 2.76) | 0.79 (0.44, 1.43) | 0.52 (0.27, 0.99) | |
| C24:1 | 2 vs. 1 | 1.22 (0.78, 1.89) | 0.89 (0.57, 1.41) | 1.30 (0.71, 2.38) | 1.03 (0.52, 2.06) |
| 3 vs. 1 | 1.52 (0.98, 2.37) | 1.18 (0.73, 1.89) | 1.35 (0.74, 2.46) | 1.00 (0.52, 1.91) | |
Multivariate models adjust for baseline age, race, education, APOE genotype, body mass index, diabetes hypertension, triglycerides, cholesterol, and postmenopausal hormone therapy (women only).